NasdaqHealth CarePharmaceutical PreparationsWALTHAM, MA

Xilio Therapeutics, Inc. XLO

Ask your AI

Estimated market cap $57.04M7.06M shares, shares as of Nov 6, 2026CIK 1840233

Insider trades, 12 mo

1 buy · 2 sells

$5,668 sold, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

10.2% of shares · 6 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q3 2026

What changed in Xilio Therapeutics, Inc.'s latest quarterly report, compared with the one before.

Filed Nov 10, 2026 · Quarter ended Sep 30, 2026

Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in Xilio Therapeutics, Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

3 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Mar 26, 2026. Insiders have two business days to file.

Recent insider trades

James Samuel Shannon Director	Mar 26 Form 4 ↗	Buy	+$43.9K 5,000 sh @ $8.79	-23.9%
Kevin M. Brennan SVP, FINANCE AND ACCOUNTING	Jan 2 Form 4 ↗	Sale 10b5-1 plan	−$1,169 1,826 sh @ $0.64	-24.6%
Christopher James Frankenfield Chief Financial Officer	Jan 2 Form 4 ↗	Sale 10b5-1 plan	−$4,499 7,030 sh @ $0.64	-24.6%
James Samuel Shannon Director	Jun 17, 2025 Form 4 ↗	Buy	+$17.3K 25,000 sh @ $0.69	-39.5%
James Samuel Shannon Director	Jun 16, 2025 Form 4 ↗	Buy	+$31.0K 45,000 sh @ $0.69	-41.1%

All XLO insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

721,531 shares

16 funds report XLO. Values checked against market prices.

Funds own 48% of shares (Q2 2026)

25 funds hold the stock.

Q3 2026: 10% · 5,560 of ~8,900 funds reported so far

Q1 202634%
Q2 202648%
Q3 2026 (so far)10%

Q3 2026. 2 new, 6 added to, 3 trimmed, 12 exited since Q2 2026.

Top 13F holders
#
1	Vanguard Capital Management LLC 13F ↗	198,181	$1.8M	+11.0%
2	Stonepine Capital Management, LLC 13F ↗	189,092	$1.7M	-16.3%
3	Merck & Co., Inc. 13F ↗	105,982	$959.1K	unchanged
4	Renaissance Technologies LLC 13F ↗	63,553	$575.2K	-0.9%
5	Morgan Stanley 13F ↗	53,674	$485.8K	-5.8%
6	Geode Capital Management, LLC 13F ↗	41,449	$375.1K	+6.1%
7	Vanguard Fiduciary Trust Co 13F ↗	28,193	$255.1K	+24.8%
8	State Street Corp 13F ↗	13,311	$120.5K	unchanged
9	HRT Financial LP 13F ↗	12,453	$112.0K	n/a
10	BlackRock, Inc. 13F ↗	10,908	$98.7K	+24.6%

One of these funds reports its values in thousands of dollars; its figures are shown in dollars.

Download CSV Every fund that holds XLO, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Xilio Therapeutics, Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Xilio Therapeutics, Inc. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q1 2026	23	—	1.97M	$16.6M
Q2 2026	25	+2	2.76M	$26.4M
Q3 2026	16	-9	721,531	$6.5M

Each point is a quarter-end, from Q1 2026 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (98422T209). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q1 2026) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes12 in 12 mo 8-K events1 in 90 days PatentsNone on record Short interestFINRA · updated Oct 15 Planned insider salesNone in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record IPO history1 registration Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: Xilio Therapeutics, Inc.
Address: 828 WINTER STREET, WALTHAM, MA 02451
Phone: 617-833-1027
Fiscal year ends: Dec 31
Filer category: Non-accelerated filer, smaller reporting company, emerging growth company
Incorporated in: DE
Listed as: XLO (Nasdaq)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$8.08−$0.17 (−2.00%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $7.31 · High $9.22Nov 13, 2026

Aug 13, 2026Low $7.31 · High $9.50Nov 13, 2026

Nov 13, 2025Low $7.14 · High $11.30Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. The stock split 1-for-14 on Mar 16, 2026; earlier prices are shown divided by the split ratio. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.